Innovent Biologics announces multiple mechanism-of-action analyses of mazdutide

Innovent Biologics (IVBXF) announced that multiple exploratory mechanism-of-action analyses of mazdutide as well as a preclinical study of IBI3030 will be showcased at the American Diabetes Association’s, ADA, 85th Scientific Sessions. The presentations include the following: Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical study. Topic: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation. Topic: Mazdutidea GCG/GLP-1R dual-agonist, alleviates MASH and hepatic fibrosis. Topic: Mazdutide, a Dual GLP-1R/GCGR Agonist, Alleviates Hyperuricemia by Modulating Hepatic Energy and Lipid Metabolism and Inhibiting Purine Pathways.